Abstract
Achieving reimbursement for regenerative medicine products is potentially a greater challenge than gaining US FDA approval, making it a decisive factor in the success or failure of small businesses. However, the mechanisms by which reimbursement is achieved are still seen as something of a ‘black box’, especially to those outside of the USA. This report aims to provide insights into the mechanisms of reimbursement and variety of payers in the USA, and to act as a starting point for a successful US reimbursement strategy. Fundamental concepts such as coverage, payment and coding are explained and linked with the factors that potentially determine the successful reimbursement of regenerative medicine products, including cost of goods and clinical study design. Finally, important considerations for the design of clinical studies that satisfy both the payers and the FDA are discussed and the key elements of a successful company strategy identified.
Papers of special note have been highlighted as: ▪ of interest
Bibliography
- 1 Plagnol AC, Rowley E, Martin P, Livesey F: Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regen. Med.4(4),549–559 (2009).▪ Provides a very informative view of the UK regenerative medicine industry from those working in it and is, therefore, not simply taken from a purely academic viewpoint.
- 2 Singh P, Williams DJ: Cell therapies: realizing the potential of this new dimension to medical therapeutics. J. Tissue. Eng. Regen. Med.2(6),307–319 (2008).
- 3 Yee GC: Peripheral blood progenitor cell transplantation: economic issues. Pharmacotherapy.18(1 Pt 2),9S–16S (1998).
- 4 Pollard TD: Life scientists and politics in the United States. Nat. Rev. Mol. Cell Biol.2,929–931 (2001).
- 5 Bodenheimer T, Grumbach K: Understanding Health Policy: A Clinical Approach (5th Edition). McGraw-Hill Medical Publishing, NY, USA (2008).
- 6 Parson A: The long journey from stem cells to medical product. Cell125,9–11 (2006).
- 7 Gajewski JL, Simmons A, Weinstein R et al.: The new apheresis and blood and marrow transplantation-related current procedural terminology codes for payment of apheresis and blood and marrow transplantation services. Biol. Blood Marrow Transplant.11(11),871–880 (2005).
- 8 Kemp P: History of regenerative medicine: looking backwards to move forwards. Regen. Med.1(5),653–669 (2006).▪ Gives a concise and comprehensive description of the history of the regenerative medicine industry from the point of view of someone that has been involved since the start and seen its evolution.
- 9 Bouchie A: Tissue engineering firms go under. Nat. Biotechnol.20(12),1178–1179 (2002).
- 10 Lysaght MJ, Hazlehurst AL: Tissue engineering: the end of the beginning. Tissue Eng.10(1/2),309–320 (2004).▪ Provides excellent data on trends and changes in the commercial landscape of the regenerative medicine industry.
- 101 Kaeding P: On track with the FDA but what about your coverage and reimbursement strategy? Wisconsin Technology Network http://wistechnology.com/articles/2362/ (Accessed July 2009)
- 102 Philips C, Thompson G: What is a QALY? Hayward Publishing Group www.whatisseries.co.uk/whatis/pdfs/What_is_a_QALY.pdf (Accessed September 2008)
- 103 Kaiser Family Foundation. “Medicare at a Glance.” Fact Sheet #1066–06 www.kff.org/medicare/upload/Medicare-At-A-Glance-Fact-Sheet-Fact-Sheet.pdf (Accessed June 2009)
- 104 Kaiser Family Foundation. “Medicaid: A Primer” www.kff.org/medicaid/upload/7334–03.pdf (Accessed January 2009)
- 105 Reaven NL: Using economic data in coverage and reimbursement decisions. BBI Newsletter www.strathealth.com/bbi_2.html (Accessed June 2009)
- 106 Organogenesis inc. Media Coverage: Articles. A conversation with Geoff MacKay www.organogenesis.com/news/media_coverage/articles/html/stemcellreport_geoff.html (Accessed January 2010)
- 107 National Health Expenditures, Forecast summary and selected tables, Office of the Actuary in the Centers for Medicare & Medicaid Services, 2008 www.cms.hhs.gov/NationalHealthExpendData/Downloads/proj2007.pdf (Accessed August 2009)
